Clinical trial · Interventional
Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
Bone Metabolic Markers, TRAP, and Zometa's Effect on Bone Metastasis Due to Lung Cancer
NCT00265200CI-TRIAL-00031932terminatedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): funding discontinued by sponsor
Summary
Brief summary (as posted)
The purpose of this study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases due to lung cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Carcinoma, Small Cell Lung | Lung Small Cell Carcinoma | ALIAS | 0.90 |
| Metastases | Lung Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| zoledronic acid | Drug | Zoledronic Acid | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- zoledronic acid
- description
- 3.0-4.0 mg by IV (in the vein), once a month for 6 months
- interventionNames
- Drug: zoledronic acid
Primary outcomes (1)
- measure
- Average Percent Change From Baseline in TRAP Levels at 2 Weeks
- timeFrame
- TRAP levels at Baseline and 2 weeks after first Zometa infusion
- description
- Change was calculated as 100% (value at baseline minus value at 2 weeks)/value at baseline
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * invasive lung cancer (small cell or non-small cell lung cancer) * osteolytic bone metastasis determined by clinical exam, bone scan/XR * age \> 18 years Exclusion Criteria: * concurrent malignancy with a second primary * renal failure (serum creatinine \> 3mg/dl) * pregnancy * active rheumatoid arthritis * intolerance to zoledronic acid
References
Publications (0)
Data not yet available
No reference posted for this study.